您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Toceranib
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Toceranib
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Toceranib图片
CAS NO:356068-94-5
包装与价格:
包装价格(元)
10mg电议
50mg电议
100mg电议
200mg电议

产品名称
托西尼布
SU11654
PHA 291639E
产品介绍
Toceranib (SU11654) 是一种口服活性受体酪氨酸激酶 (RTK) 抑制剂,能有效抑制PDGFRVEGFRKit,抑制 PDGFRβ 和 Flk-1/KDR 的Ki值分别为 5 nM 和 6 nM。Toceranib 具有抗肿瘤和抗血管生成活性,用于犬肥大细胞肿瘤的研究。
生物活性

Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibitsPDGFR,VEGFR, andKitwithKis of 5 and 6 nM forPDGFRβand Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].

IC50& Target

PDGFRβ

5 nM (Ki)

Flk-1

6 nM (Ki)

体外研究
(In Vitro)

Toceranib (SU11654) is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family, including PDGFR and Flk-1/KDR, with Kis of 5 and 6 nM, respectively[1].
To explore mechanisms of acquired Toceranib (TOC) resistance in canine MCT, three resistant sublines are generated from the Toceranib-sensitive exon 11 ITDc-kitmutant C2 cell line designated TR1, TR2, and TR3. Growth of the parental C2 cells is inhibited by Toceranib in a dose-dependent manner with an IC50of<10 nm. in contrast, tr1, tr2, and tr3 sublines are resistant to inhibition by toceranib (ic50> 1,000 nM). Sensitivity to three other KIT RTK inhibitors is similar to the observed resistance to Toceranib. The parental line as well as all three sublines retains sensitivity to the cytotoxic agents vinblastine (VBL) and CCNU. Following 72 hr culture in the presence of increasing concentrations of Toceranib, treatment naive, parental C2 cells detach from the culture flask and become rounded, shrunken, and clumped with increased exposure to Toceranib. In contrast, Toceranib-induced morphologic differences are not identified in the resistant sublines[2].

体内研究
(In Vivo)

Administration of Toceranib significantly decreases the number and percentage of Treg in the peripheral blood of dogs with cancer. Dogs receiving Toceranib and cyclophosphamide (CYC) demonstrate a significant increase in serum concentrations of IFN-γ, which is inversely correlated with Treg numbers after 6 weeks of combination treatment[3].

分子量

396.46

性状

Solid

Formula

C22H25FN4O2

CAS 号

356068-94-5

中文名称

托西尼布

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : 2.5 mg/mL(6.31 mM;Need ultrasonic)

H2O :< 0.1 mg/mL(insoluble)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM2.5223 mL12.6116 mL25.2232 mL
5 mM0.5045 mL2.5223 mL5.0446 mL
10 mM---------
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。